And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather crowded. We intend to host old friends who are passing by, hang with our short people, and take note of another turning of the calendar. And what about you? Autumn is in full swing, so enjoying a drive in the great outdoors may be in order. ‘Tis also the season to start looking for the Great Pumpkin (not to be confused with that other orange one). Or you could simply make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Bristol-Myers Squibb (BMY) disclosed its blockbuster Opdivo cancer drug failed to meet the main goal in a late-stage trial on patients with a type of lung cancer whose condition had relapsed after chemotherapy, Reuters says. The drug failed to extend overall survival in patients suffering from small-cell lung cancer when compared to patients already on chemotherapy. The failure to meets its main study goal comes nearly two months after U.S. regulators approved the drug to treat patients whose lung cancer had progressed despite undergoing two previous therapies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy